Search
BNT162a1 SARS-CoV-2 Vaccine
go.drugbank.com/drugs/DB15697Experimental[L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.
BNT162c2 SARS-CoV-2 Vaccine
go.drugbank.com/drugs/DB15698Experimental[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.
Dihydroergotamine
go.drugbank.com/drugs/DB00320ApprovedInvestigationalA 9,10alpha-dihydro derivative of ergotamine. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable s...
Guanosine
go.drugbank.com/drugs/DB02857InvestigationalGuanosine is a nucleoside comprising guanine attached to a ribose (ribofuranose) ring via a β-N9-glycosidic bond.
Xylose
go.drugbank.com/drugs/DB09419ApprovedWithdrawnXylose is a monosaccharide of the aldopentose type consisted of five carbon atoms and an aldehyde functional group. Xylose is a sugar isolated from wood. D-Xylose is a sugar widely used as a diabetic sweetener in food and beverage. Xylos...
Aceclofenac
go.drugbank.com/drugs/DB06736ApprovedIn 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, [DB00586], via chemical modification in effort to improve the gastrointestinal tolerability of the drug.
Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigationalWhile agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular
Stiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigationalStiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs. The clinical development and marketing of stiripentol were first delayed due to the drug's...
Rizatriptan
go.drugbank.com/drugs/DB00953ApprovedInvestigationalRizatriptan is a second-generation triptan and a selective 5-HT1B and 5-HT1D receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disinte...